Acceleron’s update on myostatin inhibitors

Published Date
20/09/2017
Category
Research
Orange box stating: Breaking news research

Acceleron Pharma has released an update on its neuromuscular programme. It is currently developing two drugs that aim to increase muscle mass by blocking myostatin. ACE-083 is currently being tested in people with facioscapulohumeral dystrophy (FSHD) and Charcot-Marie-Tooth (CMT) in phase 2 clinical trials. Preliminary results from the FSHD trial are expected in late 2017. ACE-2494, which works in a similar way to ACE-083 but is administered systemically, has shown promising results in preclinical studies.  A phase 1 study testing ACE-2494 is expected to be initiated later this year.        

For more information, please read Acceleron Pharma’s press release.

Keep in touch